Is thyroid cancer prognosis affected by solid organ transplantation?


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
01 2021
Historique:
received: 03 02 2020
revised: 14 05 2020
accepted: 26 06 2020
pubmed: 21 8 2020
medline: 27 4 2021
entrez: 21 8 2020
Statut: ppublish

Résumé

Thyroid nodules discovered incidentally during transplant may prolong time to transplantation. Although data suggest that incidence of thyroid cancer increases after solid organ transplantation, the impact on prognosis in differentiated thyroid cancer is not well characterized. We performed a retrospective review of patients with history of thyroid cancer and solid organ transplantation at our institution. A total of 13,037 patients underwent solid organ transplantation of which there were 94 patients with differentiated thyroid cancer (0.7%). Of these, 50 patients (53%) had cancer pre-solid organ transplantation, whereas 44 patients (47%) developed cancer post-solid organ transplantation. Papillary histology was most common (88%), followed by follicular (3%), Hurthle cell (3%), and medullary (2%) carcinomas. One patient in the post-transplant cohort died from metastatic thyroid cancer 11.8 years after transplantation. There were 5 patients in the pre-transplant group and 4 patients in the post-transplant group who had recurrent thyroid disease. There were no patients treated for differentiated thyroid cancer pre-solid organ transplantation that experienced disease recurrence after transplantation. Disease-free survival at 5 and 10 years was 95.8% and 92.1% (confidence interval 84.9-99.2%, 80.0-97.4%) in the pre-solid organ transplantation group vs 89.7% and 84.4% in the post (confidence interval: 80.0-96.3% and 79.0-93.1%, P = .363), respectively. Survival outcomes and recurrence rates in patients with thyroid cancer are not significantly affected by solid organ transplantation. A history of thyroid cancer or discovery of thyroid nodules during transplant screening should not be a contraindication for transplant listing.

Sections du résumé

BACKGROUND
Thyroid nodules discovered incidentally during transplant may prolong time to transplantation. Although data suggest that incidence of thyroid cancer increases after solid organ transplantation, the impact on prognosis in differentiated thyroid cancer is not well characterized.
METHODS
We performed a retrospective review of patients with history of thyroid cancer and solid organ transplantation at our institution.
RESULTS
A total of 13,037 patients underwent solid organ transplantation of which there were 94 patients with differentiated thyroid cancer (0.7%). Of these, 50 patients (53%) had cancer pre-solid organ transplantation, whereas 44 patients (47%) developed cancer post-solid organ transplantation. Papillary histology was most common (88%), followed by follicular (3%), Hurthle cell (3%), and medullary (2%) carcinomas. One patient in the post-transplant cohort died from metastatic thyroid cancer 11.8 years after transplantation. There were 5 patients in the pre-transplant group and 4 patients in the post-transplant group who had recurrent thyroid disease. There were no patients treated for differentiated thyroid cancer pre-solid organ transplantation that experienced disease recurrence after transplantation. Disease-free survival at 5 and 10 years was 95.8% and 92.1% (confidence interval 84.9-99.2%, 80.0-97.4%) in the pre-solid organ transplantation group vs 89.7% and 84.4% in the post (confidence interval: 80.0-96.3% and 79.0-93.1%, P = .363), respectively.
CONCLUSION
Survival outcomes and recurrence rates in patients with thyroid cancer are not significantly affected by solid organ transplantation. A history of thyroid cancer or discovery of thyroid nodules during transplant screening should not be a contraindication for transplant listing.

Identifiants

pubmed: 32814633
pii: S0039-6060(20)30443-8
doi: 10.1016/j.surg.2020.06.044
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

58-62

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Christopher Webb (C)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ. Electronic address: webb.christopher@mayo.edu.

Patricia Cronin (P)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ.

Nikita Gupta (N)

Mayo Clinic School of Medicine, Scottsdale AZ.

Jens Verhey (J)

Mayo Clinic School of Medicine, Scottsdale AZ.

Esteban Calderon (E)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ.

Adyr Moss (A)

Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Phoenix, AZ.

Amit K Mathur (AK)

Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Phoenix, AZ.

Barbara Pockaj (B)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ.

Nabil Wasif (N)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ.

Chee-Chee Stucky (CC)

Department of Surgery, Division of Surgical Oncology, Mayo Clinic, Phoenix, AZ.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH